1. Home
  2. MNSB vs GLSI Comparison

MNSB vs GLSI Comparison

Compare MNSB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNSB
  • GLSI
  • Stock Information
  • Founded
  • MNSB 2003
  • GLSI 2006
  • Country
  • MNSB United States
  • GLSI United States
  • Employees
  • MNSB N/A
  • GLSI N/A
  • Industry
  • MNSB Major Banks
  • GLSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • MNSB Finance
  • GLSI Health Care
  • Exchange
  • MNSB Nasdaq
  • GLSI Nasdaq
  • Market Cap
  • MNSB 170.1M
  • GLSI 149.5M
  • IPO Year
  • MNSB N/A
  • GLSI 2020
  • Fundamental
  • Price
  • MNSB $20.99
  • GLSI $10.45
  • Analyst Decision
  • MNSB
  • GLSI Strong Buy
  • Analyst Count
  • MNSB 0
  • GLSI 1
  • Target Price
  • MNSB N/A
  • GLSI $39.00
  • AVG Volume (30 Days)
  • MNSB 33.8K
  • GLSI 75.9K
  • Earning Date
  • MNSB 10-27-2025
  • GLSI 11-13-2025
  • Dividend Yield
  • MNSB 1.88%
  • GLSI N/A
  • EPS Growth
  • MNSB N/A
  • GLSI N/A
  • EPS
  • MNSB N/A
  • GLSI N/A
  • Revenue
  • MNSB $64,604,000.00
  • GLSI N/A
  • Revenue This Year
  • MNSB $23.19
  • GLSI N/A
  • Revenue Next Year
  • MNSB $2.92
  • GLSI N/A
  • P/E Ratio
  • MNSB N/A
  • GLSI N/A
  • Revenue Growth
  • MNSB N/A
  • GLSI N/A
  • 52 Week Low
  • MNSB $15.00
  • GLSI $8.06
  • 52 Week High
  • MNSB $22.98
  • GLSI $15.50
  • Technical
  • Relative Strength Index (RSI)
  • MNSB 40.86
  • GLSI 38.57
  • Support Level
  • MNSB $20.88
  • GLSI $11.03
  • Resistance Level
  • MNSB $21.79
  • GLSI $11.99
  • Average True Range (ATR)
  • MNSB 0.47
  • GLSI 0.70
  • MACD
  • MNSB -0.13
  • GLSI -0.08
  • Stochastic Oscillator
  • MNSB 8.66
  • GLSI 5.26

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: